Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Am J Dermatopathol ; 2024 Jul 16.
Article in English | MEDLINE | ID: mdl-39008479

ABSTRACT

ABSTRACT: Mpox, previously referred to as monkeypox, was recently deemed a public health emergency in 2022. Our understanding of potential secondary cutaneous manifestations in the setting of this infection is still evolving. We report a rare case of a man who presented with erythematous, painful subcutaneous nodules on his extremities in the setting of recent mpox infection. Biopsy of a lesion from the lower legs revealed a lobular panniculitis with lupus panniculitis-like features on pathology. He was ultimately diagnosed with a unique case of reactive panniculitis secondary to mpox.

2.
Am J Dermatopathol ; 46(1): 31-35, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37982491

ABSTRACT

ABSTRACT: Tertiary syphilis may present a diagnostic challenge due to negative nontreponemal serologies in up to 30% of cases and frequent lack of identifiable spirochetes on histopathology or other direct detection tests. We report 2 cases of round bodies staining with Treponema pallidum immunohistochemistry by light microscopy in biopsies from cutaneous syphilitic gummata. In 1 case, the finding was validated 3 times by 2 independent laboratories; in the other case, T. pallidum was detected by polymerase chain reaction in the biopsy sample. Spirochete round bodies have previously been reported in the setting of electron microscopy and fluorography, but to the best of our knowledge, have not been reported by light microscopy in a routine skin biopsy. Although the clinical implications are unclear, this may represent a helpful new paradigm for the diagnosis of tertiary syphilis.


Subject(s)
Syphilis, Cutaneous , Syphilis , Humans , Treponema pallidum , Syphilis, Cutaneous/diagnosis , Syphilis, Cutaneous/pathology , Coloring Agents , Syphilis/diagnosis , Syphilis/pathology
4.
Am J Dermatopathol ; 44(9): 650-657, 2022 Sep 01.
Article in English | MEDLINE | ID: mdl-35925282

ABSTRACT

OBJECTIVE: The integration of an artificial intelligence tool into pathologists' workflow may lead to a more accurate and timely diagnosis of melanocytic lesions, directly patient care. The objective of this study was to create and evaluate the performance of such a model in achieving clinical-grade diagnoses of Spitz nevi, dermal and junctional melanocytic nevi, and melanomas. METHODS: We created a beginner-level training environment by teaching our algorithm to perform cytologic inferences on 136,216 manually annotated tiles of hematoxylin and eosin-stained slides consisting of unequivocal melanocytic nevi, Spitz nevi, and invasive melanoma cases. We sequentially trained and tested our network to provide a final diagnosis-classification on 39 cases in total. Positive predictive value (precision) and sensitivity (recall) were used to measure our performance. RESULTS: The tile-classification algorithm predicted the 136,216 irrelevant, melanoma, melanocytic nevi, and Spitz nevi tiles at sensitivities of 96%, 93%, 94% and 73%, respectively. The final trained model was able to correctly classify and predict the correct diagnosis in 85.7% of unseen cases (n = 28), reporting at or near screening-level performances for precision and recall of melanoma (76.2%, 100.0%), melanocytic nevi (100.0%, 75.0%), and Spitz nevi (100.0%, 75.0%). CONCLUSIONS: Our pilot study proves that convolutional networks trained on cellular morphology to classify melanocytic proliferations can be used as a powerful tool to assist pathologists in screening for melanoma versus other benign lesions.


Subject(s)
Deep Learning , Melanoma , Nevus, Epithelioid and Spindle Cell , Nevus, Pigmented , Skin Neoplasms , Artificial Intelligence , Diagnosis, Differential , Humans , Melanoma/diagnosis , Melanoma/pathology , Nevus, Epithelioid and Spindle Cell/diagnosis , Nevus, Pigmented/pathology , Pilot Projects , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Melanoma, Cutaneous Malignant
5.
J Pediatr ; 248: 129-130, 2022 09.
Article in English | MEDLINE | ID: mdl-35709955
6.
Skinmed ; 20(2): 123-125, 2022.
Article in English | MEDLINE | ID: mdl-35532764

ABSTRACT

Dermatology residents have 3 years to master core competencies related to the delivery of patient care, preservation of medical professionalism, and responsible use of health care; however, it is crucial for residents to recognize other things outside of their formal curriculum that are equally vital to their training. Over the years, we have observed residents and now offer our own perspectives. We have collectively observed five extracurricular aspects commonly overlooked by dermatology residents that are important to their education and future practice. (SKINmed. 2022;20:123-125).


Subject(s)
Dermatology , Internship and Residency , Curriculum , Dermatology/education , Education, Medical, Graduate , Humans , Surveys and Questionnaires
9.
Front Oncol ; 11: 668247, 2021.
Article in English | MEDLINE | ID: mdl-34268113

ABSTRACT

Basal cell carcinoma (BCC) is a locally invasive epithelial cancer that is primarily driven by the Hedgehog (HH) pathway. Advanced BCCs are a critical subset of BCCs that frequently acquire resistance to Smoothened (SMO) inhibitors and identifying pathways that bypass SMO could provide alternative treatments for patients with advanced or metastatic BCC. Here, we use a combination of RNA-sequencing analysis of advanced human BCC tumor-normal pairs and immunostaining of human and mouse BCC samples to identify a PI3K pathway expression signature in BCC. Pharmacological inhibition of PI3K activity in BCC cells significantly reduces cell proliferation and HH signaling. However, treatment of Ptch1fl/fl ; Gli1-CreERT2 mouse BCCs with the PI3K inhibitor BKM120 results in a reduction of tumor cell growth with no significant effect on HH signaling. Downstream PI3K components aPKC and Akt1 showed a reduction in active protein, whereas their substrate, cyclin-dependent kinase inhibitor p21, showed a concomitant increase in protein stability. Our results suggest that PI3K promotes BCC tumor growth by kinase-induced p21 degradation without altering HH signaling.

10.
Exp Dermatol ; 30(3): 358-366, 2021 03.
Article in English | MEDLINE | ID: mdl-33617094

ABSTRACT

Advanced basal cell carcinomas (BCCs) are driven by the Hedgehog (HH) pathway and often possess inherent resistance to SMO inhibitors. Identifying and targeting pathways that bypass SMO could provide alternative treatments for patients with advanced or metastatic BCC. Here, we use a combination of RNA-sequencing analysis of advanced human BCC tumor-normal pairs and immunostaining of human and mouse BCC samples to identify an MTOR expression signature in BCC. Pharmacological inhibition of MTOR activity in BCC cells significantly reduces cell proliferation without affecting HH signalling. Similarly, treatment of the Ptch1 fl/fl ; Gli1-CreERT2 mouse BCC tumor model with everolimus reduces tumor growth. aPKC, a downstream target of MTOR, shows reduced activity, suggesting that MTOR promotes tumor growth by activating aPKC and demonstrating that suppressing MTOR could be a promising target for BCC patients.


Subject(s)
Carcinoma, Basal Cell/genetics , Carcinoma, Basal Cell/metabolism , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , TOR Serine-Threonine Kinases , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/drug therapy , Cell Line, Tumor , Cell Proliferation/drug effects , Everolimus/pharmacology , Everolimus/therapeutic use , Hedgehog Proteins/metabolism , Humans , Imidazoles/pharmacology , Immunohistochemistry , Mice , Patched-1 Receptor/genetics , Protein Kinase C/metabolism , Sequence Analysis, RNA , Signal Transduction/drug effects , Sirolimus/pharmacology , Skin Neoplasms/drug therapy , TOR Serine-Threonine Kinases/antagonists & inhibitors , TOR Serine-Threonine Kinases/genetics , TOR Serine-Threonine Kinases/metabolism , Triazines/pharmacology , Zinc Finger Protein GLI1/genetics
12.
Nat Commun ; 11(1): 3326, 2020 07 03.
Article in English | MEDLINE | ID: mdl-32620791

ABSTRACT

Tumour cells adapt to nutrient deprivation in vivo, yet strategies targeting the nutrient poor microenvironment remain unexplored. In melanoma, tumour cells often experience low glutamine levels, which promote cell dedifferentiation. Here, we show that dietary glutamine supplementation significantly inhibits melanoma tumour growth, prolongs survival in a transgenic melanoma mouse model, and increases sensitivity to a BRAF inhibitor. Metabolomic analysis reveals that dietary uptake of glutamine effectively increases the concentration of glutamine in tumours and its downstream metabolite, αKG, without increasing biosynthetic intermediates necessary for cell proliferation. Mechanistically, we find that glutamine supplementation uniformly alters the transcriptome in tumours. Our data further demonstrate that increase in intra-tumoural αKG concentration drives hypomethylation of H3K4me3, thereby suppressing epigenetically-activated oncogenic pathways in melanoma. Therefore, our findings provide evidence that glutamine supplementation can serve as a potential dietary intervention to block melanoma tumour growth and sensitize tumours to targeted therapy via epigenetic reprogramming.


Subject(s)
Cell Proliferation/drug effects , Dietary Supplements , Epigenesis, Genetic/drug effects , Glutamine/pharmacology , Melanoma/prevention & control , Signal Transduction/drug effects , Animals , Cell Line, Tumor , Cell Proliferation/genetics , Epigenesis, Genetic/genetics , Glutamine/administration & dosage , Histones/metabolism , Humans , Lysine/metabolism , Male , Melanoma/genetics , Melanoma/pathology , Methylation/drug effects , Mice, Nude , Signal Transduction/genetics , Transcriptome/drug effects , Xenograft Model Antitumor Assays/methods
14.
Cell Stem Cell ; 22(2): 177-190.e7, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29395054

ABSTRACT

The development of cell therapy for repairing damaged or diseased skeletal muscle has been hindered by the inability to significantly expand immature, transplantable myogenic stem cells (MuSCs) in culture. To overcome this limitation, a deeper understanding of the mechanisms regulating the transition between activated, proliferating MuSCs and differentiation-primed, poorly engrafting progenitors is needed. Here, we show that methyltransferase Setd7 facilitates such transition by regulating the nuclear accumulation of ß-catenin in proliferating MuSCs. Genetic or pharmacological inhibition of Setd7 promotes in vitro expansion of MuSCs and increases the yield of primary myogenic cell cultures. Upon transplantation, both mouse and human MuSCs expanded with a Setd7 small-molecule inhibitor are better able to repopulate the satellite cell niche, and treated mouse MuSCs show enhanced therapeutic potential in preclinical models of muscular dystrophy. Thus, Setd7 inhibition may help bypass a key obstacle in the translation of cell therapy for muscle disease.


Subject(s)
Muscle Development , Protein Methyltransferases/antagonists & inhibitors , Stem Cell Transplantation , Stem Cells/cytology , Active Transport, Cell Nucleus/drug effects , Animals , Cell Differentiation/drug effects , Cell Line , Cell Lineage/drug effects , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Proliferation/drug effects , Cell Self Renewal/drug effects , Cells, Cultured , Gene Deletion , Histone-Lysine N-Methyltransferase , Mice , Muscle, Skeletal/physiology , MyoD Protein/metabolism , Protein Binding/drug effects , Protein Methyltransferases/metabolism , Pyrrolidines/pharmacology , Regeneration/drug effects , Stem Cells/drug effects , Stem Cells/metabolism , Sulfonamides/pharmacology , Tetrahydroisoquinolines/pharmacology , beta Catenin/metabolism
15.
Geriatr Orthop Surg Rehabil ; 7(1): 33-8, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26929855

ABSTRACT

BACKGROUND: Expenditures for postacute care in total joint arthroplasty (TJA) have risen dramatically over recent decades. Therefore, efforts are underway to better identify cost savings in postacute rehabilitation centers, such as skilled nursing facilities (SNFs). The primary purpose of this study was to analyze gait training achievements in post-TJA patients in the interval between hospital discharge and the patients' first 4 days at the SNF. Identification of potential losses in therapeutic progress may lead the way for improved patient care, outcomes, and cost savings. Our hypothesis is that patients discharged to an SNF will have a decline in gait achievements upon transfer from the hospital. METHODS: A total of 68 patients who underwent TJA were included. The total distance ambulated during physical therapy (PT) was recorded for the last day of hospital therapy and the first 4 days at the SNF as well as the reported visual analog scale (VAS) pain scores. RESULTS: There was a 73% decline in distance ambulated on SNF day 0 (Hospital: 138.6 ft vs SNF: 37.9 ft; P < .001) and a 50% decline on SNF day 1 (Hospital: 103.0 ft; SNF vs 51.1 ft; P < .001) compared to the last hospital session. There were no significant differences in distance walked on SNF days 3 and 4 relative to the last hospital session. The VAS pain scores did not significantly differ on SNF days 0 and 1 compared to the last hospital day but began to significantly decline on SNF day 3 (Hospital: 4.9; SNF: 3.3; P = .02) and day 4 (Hospital: 3.9; SNF: 2.3; P = .03). CONCLUSION: There was a significant decline in ambulatory proficiency in post-TJA patients on the day of and the day following hospital discharge to an SNF. These deficits cannot be attributed to heightened pain levels. Early and progressive ambulation is a recognized component of appropriate PT following TJA. This study therefore highlights the transition from hospital to SNF as a crucial and novel target for improvement in post-TJA care.

17.
PLoS One ; 7(9): e42566, 2012.
Article in English | MEDLINE | ID: mdl-22984405

ABSTRACT

Cellular responses to Bmp ligands are regulated at multiple levels, both extracellularly and intracellularly. Therefore, the presence of these growth factors is not an accurate indicator of Bmp signaling activity. While a common approach to detect Bmp signaling activity is to determine the presence of phosphorylated forms of Smad1, 5 and 8 by immunostaining, this approach is time consuming and not quantitative. In order to provide a simpler readout system to examine the presence of Bmp signaling in developing animals, we developed BRE-gal mouse embryonic stem cells and a transgenic mouse line that specifically respond to Bmp ligand stimulation. Our reporter identifies specific transcriptional responses that are mediated by Smad1 and Smad4 with the Schnurri transcription factor complex binding to a conserved Bmp-Responsive Element (BRE), originally identified among Drosophila, Xenopus and human Bmp targets. Our BRE-gal mES cells specifically respond to Bmp ligands at concentrations as low as 5 ng/ml; and BRE-gal reporter mice, derived from the BRE-gal mES cells, show dynamic activity in many cellular sites, including extraembryonic structures and mammary glands, thereby making this a useful scientific tool.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Gene Expression Regulation, Developmental , Transcription, Genetic , Animals , Base Sequence , Binding Sites , Bone Morphogenetic Proteins/pharmacology , Cell Line , Embryo, Mammalian/cytology , Embryo, Mammalian/drug effects , Embryo, Mammalian/metabolism , Embryonic Stem Cells/cytology , Embryonic Stem Cells/drug effects , Embryonic Stem Cells/metabolism , Female , Gastrulation/drug effects , Gastrulation/genetics , Gene Expression Regulation, Developmental/drug effects , Genes, Reporter/genetics , Humans , Ligands , Mice , Mice, Transgenic , Molecular Sequence Data , Pregnancy , Primitive Streak/drug effects , Primitive Streak/metabolism , Protein Binding/drug effects , Response Elements/genetics , Signal Transduction/drug effects , Signal Transduction/genetics , Smad Proteins/metabolism , Transcription, Genetic/drug effects
18.
PLoS One ; 7(9): e44009, 2012.
Article in English | MEDLINE | ID: mdl-22984456

ABSTRACT

Insights into Bone morphogenetic protein (Bmp) functions during forebrain development have been limited by a lack of Bmp signaling readouts. Here we used a novel Bmp signaling reporter ("BRE-gal" mice) to study Bmp signaling in the dorsal telencephalon. At early stages, BRE-gal expression was restricted to the dorsal telencephalic midline. At later stages, strong BRE-gal expression occurred in neurons of the marginal zone and dentate gyrus. Comparisons to nuclear phospho-Smad1/5/8 (pSmad) and Msx1 indicated that BRE-gal expression occurred exclusively in neural cells with high-level Bmp signaling. BRE-gal responsiveness to Bmps was confirmed in reporter-negative cortical cells cultured with Bmp4, and both in vivo and in vitro, BRE-gal expression was switch-like, or ultrasensitive. In the early dorsal telencephalon, BRE-gal expression negatively correlated with the cortical selector gene Lhx2, indicating a BRE-gal expression border that coincides with the cortex-hem boundary. However, in Lhx2 null chimeras, neither BRE-gal nor nuclear pSmad increases were observed in ectopic hem cells. These findings establish BRE-gal as an ultrasensitive reporter of Bmp signaling in the dorsal telencephalon, imply that hem fate can be specified at different Bmp signaling intensities, and suggest that Lhx2 primarily regulates the responses to--rather than the intensity of--Bmp signaling in dorsal telencephalic cells.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Cell Lineage , Cerebral Cortex/cytology , Cerebral Cortex/embryology , Genes, Reporter/genetics , Signal Transduction , Animals , Animals, Newborn , Bone Morphogenetic Protein 4/metabolism , Bone Morphogenetic Proteins/genetics , Cell Differentiation , Cerebral Cortex/metabolism , Hippocampus/cytology , Hippocampus/embryology , MSX1 Transcription Factor/metabolism , Mice , Neurons/cytology , Neurons/metabolism , Organ Specificity , Phosphorylation , Smad Proteins/metabolism , beta-Galactosidase/metabolism
19.
Proc Natl Acad Sci U S A ; 105(9): 3398-403, 2008 Mar 04.
Article in English | MEDLINE | ID: mdl-18292231

ABSTRACT

Conversions of signaling gradients into sharp "all-or-none" borders are fundamental to tissue and organismal development. However, whether such conversions can be meaningfully reduced to dissociated cells in culture has been uncertain. Here we describe ultrasensitivity, the phenomenon equivalent to an all-or-none response, in dissociated neural precursor cells (NPCs) exposed to bone morphogenetic protein 4 (Bmp4). NPC ultrasensitivity is evident at the population and single-cell levels based on Msx1 induction, a well known Bmp target response, and occurs in the context of gene expression changes consistent with Bmp4 activity as a morphogen. Dissociated NPCs also display immediate early kinetics and irreversibility for Msx1 induction after brief Bmp4 exposure, which are attractive features for initial border formation. Relevance to border formation in vivo is provided by Bmp4 gain-of-function studies in explants and evidence for single-cell ultrasensitivity in normal and mutant Bmp gradient contexts in the developing forebrain. Together, these studies demonstrate relatively simple, robust, and reducible cell-intrinsic properties that contribute to developmental border formation within a signaling gradient.


Subject(s)
Bone Morphogenetic Proteins/pharmacology , Neurons/cytology , Prosencephalon/cytology , Stem Cells/cytology , Animals , Bone Morphogenetic Protein 4 , Embryo, Mammalian , Gene Expression Regulation , Humans , In Vitro Techniques , MSX1 Transcription Factor/genetics , Mice , RNA, Messenger
SELECTION OF CITATIONS
SEARCH DETAIL